Amendment: SEC Form SC 13G/A filed by Xilio Therapeutics Inc.
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/21/2022 | $7.00 | Buy | Chardan Capital Markets |
| 1/10/2022 | $36.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $40.00 | Buy | Guggenheim |
| 11/16/2021 | $31.00 | Outperform | Raymond James |
| 11/16/2021 | Outperform | Cowen & Co. | |
| 11/16/2021 | $32.00 | Overweight | Morgan Stanley |
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
10-Q - Xilio Therapeutics, Inc. (0001840233) (Filer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
8-K - Xilio Therapeutics, Inc. (0001840233) (Filer)
-SEC Filing
Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically "cold" tumors Complete resolution of a metastatic liver lesion observed in a patient with microsatellite stable colorectal cancer (MSS CRC) Safety data indicated combination of vilastobart and atezolizumab was generally well-tolerated and support the potential of vilastobart to be a differentiated next-generation anti-CTLA-4 in combination with PD-(L)1 inhibitors Continue to anticipate initial data from Phase 2 trial for combination of vilastobart and atezolizumab in metastatic
Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at the SITC Annual Meeting Expect to report initial Phase 2 data in microsatellite stable colorectal cancer (MSS CRC) for vilastobart in combination with atezolizumab in the fourth quarter of 2024 Expect to report Phase 1 data for XTX301, a tumor-activated IL-12, in the fourth quarter of 2024 WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people
WALTHAM, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that initial data from its Phase 1C dose escalation of XTX101 (vilastobart) in combination with atezolizumab in patients with advanced solid tumors will be presented in a late-breaker poster session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting taking place in Houston, Texas, from November 6-10, 2024. Poster presentation details: Title: Phase 1/2 Study of Vilastobart (formerly XTX101), a Tumor-Activated, Fc-enhanced Anti-CTL
Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat, immunologically "cold" tumors Complete resolution of a metastatic liver lesion observed in a patient with microsatellite stable colorectal cancer (MSS CRC) Safety data indicated combination of vilastobart and atezolizumab was generally well-tolerated and support the potential of vilastobart to be a differentiated next-generation anti-CTLA-4 in combination with PD-(L)1 inhibitors Continue to anticipate initial data from Phase 2 trial for combination of vilastobart and atezolizumab in metastatic
Initial evidence of dose-dependent disease control rate with 50% disease control rate at higher doses (≥2.8 mg/kg) and 31% disease control rate across all dose levels in a range of solid tumor types, including cold tumors Treatment-related adverse events primarily Grade 1-2 at doses up to 4 mg/kg administered once every three weeks in outpatient setting, with no reported signs or symptoms of vascular leak syndrome Two patients continuing treatment for more than 1 year, demonstrating XTX202 was well-tolerated with repeated, long-term dosing Plan to evaluate XTX202 as a monotherapy in ongoing Phase 2 proof-of-concept trial at 4.0 mg/kg in patients with advanced melanoma and renal cell carci
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. The call will feature
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G/A - Xilio Therapeutics, Inc. (0001840233) (Subject)
SC 13G - Xilio Therapeutics, Inc. (0001840233) (Subject)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
3 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
4 - Xilio Therapeutics, Inc. (0001840233) (Issuer)
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Aoife Brennan, M.D., and James Shannon, M.D., to the company's board of directors. "On behalf of the entire board of directors, it is a privilege to welcome Aoife and James, both well-recognized biotech industry veterans, to the board of directors," said Paul Clancy, chair of the board of directors of Xilio Therapeutics. "Their extensive experience spanning all stages of drug development will be invaluable as Xilio progresses its
XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no signs of vascular leak syndrome XTX301, a tumor-activated IL-12, received FDA clearance for IND application; anticipate initiating patient dosing in Phase 1 clinical trial in first quarter of 2023 Plan to focus resources on advancing clinical-stage cytokine programs and will seek to partner XTX101, a tumor-activated anti-CTLA-4, to advance beyond ongoing Phase 1 monotherapy cohorts $139.1 million in cash and cash equivalents as of September 30, 2022, with anticipate
WALTHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced the appointment of Tomas J. Heyman to the company's board of directors. Mr. Heyman is a biopharmaceutical veteran with nearly 40 years of leadership and management expertise in corporate strategy, business development and venture capital from his tenure with Johnson & Johnson (J&J). In addition, the company announced that John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, will serve as a strategic advisor to Xilio's board of directors and its executive team.
Chardan Capital Markets initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $36.00
Guggenheim initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $40.00